| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hip Prosthesis | 122 | 2023 | 605 | 16.060 |
Why?
|
| Arthroplasty, Replacement, Hip | 93 | 2023 | 863 | 13.000 |
Why?
|
| Prosthesis Failure | 102 | 2023 | 556 | 10.810 |
Why?
|
| Metals | 51 | 2022 | 160 | 7.580 |
Why?
|
| Cobalt | 41 | 2023 | 116 | 6.530 |
Why?
|
| Prosthesis Design | 84 | 2023 | 502 | 5.670 |
Why?
|
| Chromium | 32 | 2020 | 92 | 5.480 |
Why?
|
| Metal-on-Metal Joint Prostheses | 20 | 2022 | 57 | 5.390 |
Why?
|
| Titanium | 52 | 2020 | 209 | 5.270 |
Why?
|
| Polyethylene | 23 | 2021 | 116 | 4.150 |
Why?
|
| Arthroplasty, Replacement, Knee | 38 | 2021 | 696 | 3.930 |
Why?
|
| Orthopedics | 15 | 2021 | 127 | 3.700 |
Why?
|
| Osteolysis | 35 | 2021 | 149 | 3.480 |
Why?
|
| Biocompatible Materials | 27 | 2013 | 114 | 3.340 |
Why?
|
| Humans | 283 | 2023 | 29337 | 3.220 |
Why?
|
| Corrosion | 43 | 2023 | 139 | 3.030 |
Why?
|
| Prostheses and Implants | 22 | 2021 | 166 | 2.890 |
Why?
|
| Foreign-Body Reaction | 14 | 2017 | 32 | 2.880 |
Why?
|
| Chromium Alloys | 16 | 2023 | 48 | 2.560 |
Why?
|
| Alloys | 33 | 2018 | 102 | 2.480 |
Why?
|
| Knee Prosthesis | 23 | 2021 | 248 | 2.340 |
Why?
|
| Angioedemas, Hereditary | 9 | 2023 | 9 | 2.320 |
Why?
|
| Hip Joint | 20 | 2017 | 367 | 2.030 |
Why?
|
| Male | 135 | 2022 | 15621 | 2.030 |
Why?
|
| Device Removal | 15 | 2021 | 85 | 1.980 |
Why?
|
| Complement C1 Inhibitor Protein | 10 | 2023 | 10 | 1.940 |
Why?
|
| Theta Rhythm | 4 | 2020 | 8 | 1.910 |
Why?
|
| Hippocampus | 6 | 2023 | 274 | 1.910 |
Why?
|
| Female | 131 | 2021 | 16197 | 1.900 |
Why?
|
| Postoperative Complications | 23 | 2021 | 957 | 1.890 |
Why?
|
| Middle Aged | 109 | 2021 | 9823 | 1.840 |
Why?
|
| Neurons | 4 | 2021 | 374 | 1.820 |
Why?
|
| Orthopedic Procedures | 8 | 2020 | 317 | 1.810 |
Why?
|
| Reoperation | 54 | 2021 | 932 | 1.800 |
Why?
|
| Arthroplasty, Replacement | 11 | 2021 | 147 | 1.700 |
Why?
|
| Adult | 89 | 2021 | 8601 | 1.600 |
Why?
|
| Hypersensitivity | 10 | 2021 | 48 | 1.580 |
Why?
|
| Joint Prosthesis | 12 | 2019 | 83 | 1.540 |
Why?
|
| Temporal Lobe | 4 | 2021 | 105 | 1.490 |
Why?
|
| Space Perception | 3 | 2015 | 28 | 1.470 |
Why?
|
| Aged | 94 | 2021 | 9448 | 1.350 |
Why?
|
| Lymphocyte Activation | 8 | 2020 | 209 | 1.340 |
Why?
|
| Materials Testing | 15 | 2021 | 137 | 1.280 |
Why?
|
| Societies, Medical | 3 | 2021 | 190 | 1.250 |
Why?
|
| Risk Assessment | 14 | 2021 | 679 | 1.230 |
Why?
|
| Surface Properties | 34 | 2021 | 144 | 1.220 |
Why?
|
| Models, Theoretical | 4 | 2020 | 91 | 1.050 |
Why?
|
| Biomedical Research | 4 | 2009 | 81 | 1.030 |
Why?
|
| Brain Neoplasms | 4 | 2021 | 124 | 1.030 |
Why?
|
| Venous Thromboembolism | 4 | 2012 | 37 | 1.020 |
Why?
|
| Spatial Memory | 2 | 2021 | 3 | 1.010 |
Why?
|
| Mental Recall | 2 | 2023 | 74 | 1.000 |
Why?
|
| Entorhinal Cortex | 2 | 2015 | 37 | 0.990 |
Why?
|
| Osteoarthritis, Hip | 10 | 2014 | 94 | 0.970 |
Why?
|
| Lymphocytes | 8 | 2021 | 110 | 0.970 |
Why?
|
| Epilepsy | 3 | 2015 | 104 | 0.940 |
Why?
|
| Models, Biological | 6 | 2019 | 343 | 0.920 |
Why?
|
| Practice Guidelines as Topic | 4 | 2014 | 333 | 0.920 |
Why?
|
| Spatial Navigation | 3 | 2021 | 6 | 0.900 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2021 | 1221 | 0.900 |
Why?
|
| Algorithms | 5 | 2021 | 400 | 0.890 |
Why?
|
| Musculoskeletal Diseases | 3 | 2013 | 41 | 0.880 |
Why?
|
| Total Disc Replacement | 2 | 2012 | 16 | 0.880 |
Why?
|
| Memory, Episodic | 2 | 2021 | 116 | 0.870 |
Why?
|
| Ions | 10 | 2016 | 54 | 0.860 |
Why?
|
| Emotions | 1 | 2023 | 90 | 0.860 |
Why?
|
| Spatial Behavior | 2 | 2013 | 14 | 0.850 |
Why?
|
| Angioedema | 1 | 2021 | 3 | 0.820 |
Why?
|
| Acetabulum | 17 | 2012 | 208 | 0.810 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 86 | 0.810 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 89 | 0.810 |
Why?
|
| Models, Immunological | 2 | 2020 | 9 | 0.800 |
Why?
|
| Aged, 80 and over | 45 | 2021 | 4851 | 0.790 |
Why?
|
| Particle Size | 20 | 2014 | 78 | 0.790 |
Why?
|
| Equipment Failure Analysis | 16 | 2017 | 106 | 0.790 |
Why?
|
| Biomarkers | 12 | 2023 | 689 | 0.780 |
Why?
|
| Disease Management | 2 | 2021 | 114 | 0.780 |
Why?
|
| Treatment Outcome | 24 | 2023 | 3478 | 0.780 |
Why?
|
| Computer-Assisted Instruction | 1 | 2021 | 25 | 0.780 |
Why?
|
| Osteoblasts | 9 | 2014 | 63 | 0.760 |
Why?
|
| Consensus | 1 | 2021 | 105 | 0.760 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 27 | 0.750 |
Why?
|
| Animals | 37 | 2021 | 4552 | 0.750 |
Why?
|
| Prospective Studies | 22 | 2020 | 1811 | 0.750 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 87 | 0.730 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2017 | 222 | 0.730 |
Why?
|
| Cytokines | 15 | 2019 | 347 | 0.710 |
Why?
|
| Gait | 2 | 2020 | 404 | 0.710 |
Why?
|
| Polyethylenes | 15 | 2020 | 50 | 0.700 |
Why?
|
| Glioblastoma | 1 | 2019 | 10 | 0.700 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2009 | 5 | 0.680 |
Why?
|
| Betacoronavirus | 1 | 2020 | 75 | 0.680 |
Why?
|
| Joint Diseases | 3 | 2012 | 110 | 0.680 |
Why?
|
| Stress, Mechanical | 12 | 2020 | 166 | 0.670 |
Why?
|
| Femur | 17 | 2019 | 396 | 0.670 |
Why?
|
| Surgeons | 1 | 2020 | 76 | 0.670 |
Why?
|
| Tantalum | 3 | 2007 | 34 | 0.650 |
Why?
|
| Lumbosacral Plexus | 1 | 2017 | 6 | 0.640 |
Why?
|
| Quality of Life | 3 | 2023 | 662 | 0.640 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 51 | 0.620 |
Why?
|
| Monocytes | 11 | 2016 | 116 | 0.620 |
Why?
|
| Time Factors | 26 | 2020 | 1616 | 0.610 |
Why?
|
| Retrospective Studies | 18 | 2021 | 3273 | 0.610 |
Why?
|
| Macrophages | 11 | 2021 | 128 | 0.600 |
Why?
|
| Vitallium | 6 | 2023 | 25 | 0.590 |
Why?
|
| Chronic Pain | 2 | 2023 | 112 | 0.590 |
Why?
|
| Ceramics | 7 | 2015 | 23 | 0.580 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 106 | 0.580 |
Why?
|
| Follow-Up Studies | 29 | 2021 | 1830 | 0.580 |
Why?
|
| Young Adult | 14 | 2020 | 1932 | 0.580 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 184 | 0.580 |
Why?
|
| Poisoning | 2 | 2013 | 3 | 0.570 |
Why?
|
| Synovial Fluid | 7 | 2018 | 123 | 0.540 |
Why?
|
| Bone Resorption | 14 | 2021 | 104 | 0.540 |
Why?
|
| United States | 12 | 2021 | 2333 | 0.540 |
Why?
|
| Hypersensitivity, Delayed | 5 | 2019 | 21 | 0.530 |
Why?
|
| Prosthesis-Related Infections | 5 | 2015 | 214 | 0.520 |
Why?
|
| Nickel | 7 | 2019 | 29 | 0.520 |
Why?
|
| Foreign Bodies | 4 | 2020 | 25 | 0.510 |
Why?
|
| Osteoarthritis, Knee | 5 | 2014 | 381 | 0.510 |
Why?
|
| Brain Mapping | 2 | 2013 | 195 | 0.510 |
Why?
|
| Movement | 4 | 2018 | 143 | 0.510 |
Why?
|
| Diagnosis, Differential | 5 | 2021 | 389 | 0.500 |
Why?
|
| Viscosupplementation | 1 | 2014 | 8 | 0.500 |
Why?
|
| Hereditary Angioedema Types I and II | 3 | 2019 | 3 | 0.500 |
Why?
|
| Awards and Prizes | 1 | 2014 | 24 | 0.500 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2018 | 770 | 0.490 |
Why?
|
| Synovial Membrane | 5 | 2008 | 81 | 0.490 |
Why?
|
| Biomechanical Phenomena | 10 | 2020 | 668 | 0.480 |
Why?
|
| Repetition Priming | 1 | 2013 | 1 | 0.470 |
Why?
|
| Occipital Lobe | 1 | 2013 | 13 | 0.470 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2012 | 218 | 0.470 |
Why?
|
| Brain Waves | 1 | 2013 | 8 | 0.470 |
Why?
|
| Inflammation | 6 | 2021 | 344 | 0.460 |
Why?
|
| Electroencephalography | 5 | 2021 | 140 | 0.460 |
Why?
|
| Cost of Illness | 1 | 2013 | 54 | 0.460 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2013 | 22 | 0.460 |
Why?
|
| Intervertebral Disc | 3 | 2017 | 212 | 0.460 |
Why?
|
| Guided Tissue Regeneration | 2 | 2018 | 10 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2023 | 113 | 0.450 |
Why?
|
| Cervical Vertebrae | 1 | 2017 | 349 | 0.450 |
Why?
|
| Fibroblasts | 10 | 2008 | 95 | 0.440 |
Why?
|
| Radiography | 22 | 2018 | 678 | 0.440 |
Why?
|
| Cysts | 1 | 2012 | 16 | 0.430 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 4 | 2021 | 11 | 0.430 |
Why?
|
| Molybdenum | 6 | 2021 | 22 | 0.420 |
Why?
|
| Memory | 1 | 2013 | 318 | 0.420 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 12 | 0.410 |
Why?
|
| Health Promotion | 1 | 2013 | 161 | 0.410 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2012 | 116 | 0.400 |
Why?
|
| Medical Laboratory Science | 2 | 2008 | 10 | 0.400 |
Why?
|
| Anterior Cruciate Ligament Reconstruction | 1 | 2014 | 235 | 0.390 |
Why?
|
| Metals, Heavy | 3 | 2016 | 7 | 0.380 |
Why?
|
| Risk Factors | 11 | 2019 | 2443 | 0.380 |
Why?
|
| Biological Clocks | 1 | 2010 | 16 | 0.370 |
Why?
|
| Nuclear Proteins | 3 | 2013 | 88 | 0.370 |
Why?
|
| Neocortex | 1 | 2010 | 34 | 0.370 |
Why?
|
| Inflammasomes | 4 | 2021 | 15 | 0.370 |
Why?
|
| Functional Laterality | 1 | 2010 | 91 | 0.360 |
Why?
|
| Pandemics | 3 | 2021 | 236 | 0.360 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1442 | 0.360 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 81 | 0.360 |
Why?
|
| Health Education | 1 | 2009 | 39 | 0.350 |
Why?
|
| T-Lymphocytes | 2 | 2010 | 211 | 0.350 |
Why?
|
| Bone Cements | 14 | 2012 | 99 | 0.350 |
Why?
|
| Health Services Research | 1 | 2009 | 41 | 0.350 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2020 | 21 | 0.340 |
Why?
|
| Immunity, Cellular | 4 | 2020 | 65 | 0.340 |
Why?
|
| Rheumatology | 1 | 2009 | 81 | 0.330 |
Why?
|
| Cells, Cultured | 16 | 2019 | 676 | 0.330 |
Why?
|
| Plasma Kallikrein | 2 | 2018 | 2 | 0.320 |
Why?
|
| Metal Nanoparticles | 4 | 2018 | 11 | 0.320 |
Why?
|
| Signal Transduction | 7 | 2019 | 482 | 0.320 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 90 | 0.320 |
Why?
|
| Tibia | 5 | 2020 | 259 | 0.320 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 219 | 0.320 |
Why?
|
| Cross-Linking Reagents | 1 | 2007 | 15 | 0.320 |
Why?
|
| Radiology Information Systems | 1 | 2007 | 3 | 0.320 |
Why?
|
| Microscopy, Electron, Scanning | 15 | 2017 | 86 | 0.310 |
Why?
|
| Glycoproteins | 1 | 2007 | 58 | 0.310 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 521 | 0.310 |
Why?
|
| Spleen | 2 | 2004 | 51 | 0.300 |
Why?
|
| Vanadium | 4 | 2008 | 7 | 0.300 |
Why?
|
| Caspase 1 | 4 | 2021 | 14 | 0.300 |
Why?
|
| Lumbar Vertebrae | 1 | 2012 | 487 | 0.290 |
Why?
|
| Polymers | 3 | 2009 | 42 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 260 | 0.290 |
Why?
|
| Asthma | 2 | 2020 | 138 | 0.290 |
Why?
|
| Biomedical Technology | 1 | 2006 | 7 | 0.290 |
Why?
|
| Europium | 2 | 2020 | 5 | 0.290 |
Why?
|
| Stearates | 2 | 2020 | 5 | 0.290 |
Why?
|
| Mice | 15 | 2021 | 1607 | 0.290 |
Why?
|
| Cell Division | 8 | 2004 | 113 | 0.290 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2016 | 33 | 0.290 |
Why?
|
| Conflict of Interest | 1 | 2006 | 18 | 0.280 |
Why?
|
| Electrodes | 2 | 2020 | 16 | 0.280 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 34 | 0.280 |
Why?
|
| Weight-Bearing | 6 | 2011 | 164 | 0.280 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2016 | 215 | 0.270 |
Why?
|
| Liver | 2 | 2004 | 173 | 0.270 |
Why?
|
| Complement Inactivating Agents | 2 | 2019 | 4 | 0.270 |
Why?
|
| Blood Proteins | 4 | 2012 | 20 | 0.270 |
Why?
|
| Cell Transplantation | 1 | 2005 | 29 | 0.270 |
Why?
|
| Evidence-Based Medicine | 4 | 2012 | 208 | 0.260 |
Why?
|
| Environmental Monitoring | 1 | 2004 | 8 | 0.260 |
Why?
|
| Osteosarcoma | 3 | 2013 | 29 | 0.260 |
Why?
|
| Bone Remodeling | 4 | 2021 | 44 | 0.260 |
Why?
|
| Medicare | 2 | 2018 | 121 | 0.260 |
Why?
|
| Aluminum | 4 | 1999 | 11 | 0.260 |
Why?
|
| Injections, Subcutaneous | 6 | 2020 | 32 | 0.260 |
Why?
|
| Phagocytosis | 10 | 2013 | 55 | 0.260 |
Why?
|
| Cartilage, Articular | 3 | 2007 | 524 | 0.260 |
Why?
|
| Metal Ceramic Alloys | 1 | 2004 | 3 | 0.250 |
Why?
|
| Child | 7 | 2023 | 1346 | 0.240 |
Why?
|
| Spinal Diseases | 1 | 2006 | 150 | 0.240 |
Why?
|
| Biofilms | 1 | 2003 | 15 | 0.230 |
Why?
|
| Elective Surgical Procedures | 3 | 2012 | 43 | 0.230 |
Why?
|
| Postoperative Period | 3 | 2016 | 288 | 0.230 |
Why?
|
| Pain Measurement | 6 | 2018 | 462 | 0.230 |
Why?
|
| Acute Pain | 1 | 2023 | 21 | 0.230 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2021 | 60 | 0.220 |
Why?
|
| Bone Neoplasms | 2 | 2013 | 101 | 0.220 |
Why?
|
| Gene Expression Regulation | 4 | 2014 | 284 | 0.220 |
Why?
|
| Drug Hypersensitivity | 2 | 2019 | 17 | 0.220 |
Why?
|
| Amygdala | 1 | 2023 | 50 | 0.220 |
Why?
|
| Neuroblastoma | 2 | 2013 | 19 | 0.220 |
Why?
|
| Oncogene Proteins | 2 | 2013 | 7 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2013 | 21 | 0.220 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 145 | 0.220 |
Why?
|
| Spine | 1 | 2003 | 121 | 0.220 |
Why?
|
| Prosthesis Fitting | 2 | 2020 | 22 | 0.220 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 29 | 0.210 |
Why?
|
| Microscopy, Electron, Transmission | 4 | 2013 | 30 | 0.210 |
Why?
|
| User-Computer Interface | 2 | 2013 | 25 | 0.210 |
Why?
|
| Arthritis, Gouty | 1 | 2001 | 2 | 0.210 |
Why?
|
| Growth Substances | 1 | 2001 | 41 | 0.210 |
Why?
|
| Double-Blind Method | 6 | 2020 | 503 | 0.210 |
Why?
|
| Pilot Projects | 3 | 2020 | 394 | 0.210 |
Why?
|
| Clinical Competence | 2 | 2021 | 230 | 0.210 |
Why?
|
| Absorbable Implants | 1 | 2001 | 24 | 0.210 |
Why?
|
| Joint Capsule | 2 | 2019 | 43 | 0.200 |
Why?
|
| Femoral Neoplasms | 2 | 1992 | 6 | 0.200 |
Why?
|
| Collagen Type I | 1 | 2021 | 18 | 0.200 |
Why?
|
| Patella | 5 | 2006 | 81 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2013 | 89 | 0.200 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2008 | 30 | 0.200 |
Why?
|
| Forecasting | 2 | 2020 | 117 | 0.200 |
Why?
|
| Oxidation-Reduction | 3 | 2015 | 73 | 0.200 |
Why?
|
| Biomedical Engineering | 1 | 2001 | 6 | 0.200 |
Why?
|
| Arthritis, Infectious | 2 | 2018 | 59 | 0.200 |
Why?
|
| Neoplasms | 6 | 2017 | 247 | 0.200 |
Why?
|
| Cohort Studies | 5 | 2016 | 1939 | 0.200 |
Why?
|
| Cell Adhesion | 1 | 2001 | 43 | 0.200 |
Why?
|
| Eosinophils | 2 | 2020 | 47 | 0.200 |
Why?
|
| Cell Proliferation | 4 | 2013 | 201 | 0.200 |
Why?
|
| Disease Progression | 5 | 2018 | 787 | 0.200 |
Why?
|
| Interleukin-1beta | 7 | 2016 | 55 | 0.200 |
Why?
|
| Adolescent | 6 | 2019 | 2279 | 0.200 |
Why?
|
| Ethics, Medical | 2 | 2006 | 17 | 0.200 |
Why?
|
| Cell Survival | 11 | 2014 | 169 | 0.190 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 3 | 2019 | 11 | 0.190 |
Why?
|
| Cross Reactions | 1 | 2020 | 26 | 0.190 |
Why?
|
| Viral Vaccines | 1 | 2020 | 5 | 0.190 |
Why?
|
| Cell Line | 7 | 2016 | 298 | 0.190 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 17 | 0.190 |
Why?
|
| Internal Fixators | 3 | 2016 | 54 | 0.190 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 553 | 0.190 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 15 | 0.190 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2021 | 148 | 0.190 |
Why?
|
| Occupational Health | 1 | 2020 | 21 | 0.190 |
Why?
|
| Wounds, Penetrating | 1 | 2020 | 10 | 0.190 |
Why?
|
| Granuloma, Foreign-Body | 2 | 1997 | 6 | 0.190 |
Why?
|
| Immunoglobulins | 1 | 2020 | 28 | 0.190 |
Why?
|
| Knee Joint | 7 | 2007 | 797 | 0.190 |
Why?
|
| Coated Materials, Biocompatible | 6 | 2010 | 41 | 0.190 |
Why?
|
| Task Performance and Analysis | 1 | 2020 | 55 | 0.190 |
Why?
|
| Minimally Invasive Surgical Procedures | 5 | 2007 | 300 | 0.180 |
Why?
|
| Military Personnel | 1 | 2020 | 34 | 0.180 |
Why?
|
| Friction | 4 | 2017 | 20 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 437 | 0.180 |
Why?
|
| Range of Motion, Articular | 7 | 2016 | 699 | 0.180 |
Why?
|
| Patient Safety | 1 | 2020 | 51 | 0.180 |
Why?
|
| In Vitro Techniques | 4 | 2019 | 213 | 0.180 |
Why?
|
| Electrochemistry | 5 | 2017 | 44 | 0.180 |
Why?
|
| Tissue Adhesives | 1 | 2019 | 8 | 0.180 |
Why?
|
| DNA Damage | 2 | 2010 | 30 | 0.180 |
Why?
|
| Tissue Scaffolds | 1 | 2019 | 22 | 0.180 |
Why?
|
| Polystyrenes | 4 | 1997 | 8 | 0.180 |
Why?
|
| Penicillins | 1 | 2019 | 12 | 0.170 |
Why?
|
| Inflammation Mediators | 4 | 2009 | 83 | 0.170 |
Why?
|
| Walking | 1 | 2021 | 252 | 0.170 |
Why?
|
| Tendons | 3 | 2006 | 218 | 0.170 |
Why?
|
| Personality Assessment | 1 | 2019 | 38 | 0.170 |
Why?
|
| Cellular Senescence | 1 | 1999 | 18 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2020 | 218 | 0.170 |
Why?
|
| Hematopoiesis | 1 | 2018 | 11 | 0.170 |
Why?
|
| Repressor Proteins | 1 | 1999 | 29 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 31 | 0.170 |
Why?
|
| Bone Marrow | 2 | 2018 | 73 | 0.170 |
Why?
|
| Grid Cells | 1 | 2018 | 1 | 0.170 |
Why?
|
| Th17 Cells | 1 | 2019 | 28 | 0.170 |
Why?
|
| Neuronavigation | 1 | 2018 | 6 | 0.170 |
Why?
|
| Stereotaxic Techniques | 1 | 2018 | 27 | 0.170 |
Why?
|
| Dogs | 3 | 2015 | 253 | 0.170 |
Why?
|
| Sex Factors | 3 | 2017 | 496 | 0.170 |
Why?
|
| Odds Ratio | 2 | 2019 | 285 | 0.170 |
Why?
|
| Regenerative Medicine | 1 | 2018 | 5 | 0.170 |
Why?
|
| Immunity, Innate | 2 | 2021 | 90 | 0.170 |
Why?
|
| Osseointegration | 5 | 2007 | 76 | 0.170 |
Why?
|
| Porosity | 6 | 2007 | 71 | 0.170 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 1251 | 0.160 |
Why?
|
| Patient Selection | 4 | 2011 | 232 | 0.160 |
Why?
|
| Patient Care Bundles | 1 | 2018 | 5 | 0.160 |
Why?
|
| Risk Adjustment | 1 | 2018 | 12 | 0.160 |
Why?
|
| Cementation | 7 | 2021 | 36 | 0.160 |
Why?
|
| Bone and Bones | 6 | 2014 | 119 | 0.160 |
Why?
|
| Femur Head | 3 | 2023 | 66 | 0.160 |
Why?
|
| Nasopharyngitis | 1 | 2017 | 2 | 0.160 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2017 | 33 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 68 | 0.160 |
Why?
|
| Apoptosis | 3 | 2013 | 251 | 0.160 |
Why?
|
| Interleukin-6 | 5 | 2010 | 108 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2017 | 62 | 0.150 |
Why?
|
| Safety Management | 2 | 2020 | 24 | 0.150 |
Why?
|
| Infant, Newborn | 2 | 2021 | 604 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2017 | 66 | 0.150 |
Why?
|
| Stainless Steel | 3 | 2003 | 17 | 0.150 |
Why?
|
| ROC Curve | 1 | 2017 | 138 | 0.150 |
Why?
|
| Internship and Residency | 2 | 2019 | 211 | 0.150 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.150 |
Why?
|
| RNA, Messenger | 9 | 2007 | 323 | 0.150 |
Why?
|
| Cross-Over Studies | 4 | 2019 | 78 | 0.150 |
Why?
|
| Pain Management | 1 | 2018 | 143 | 0.140 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2016 | 32 | 0.140 |
Why?
|
| Proteins | 3 | 2010 | 72 | 0.140 |
Why?
|
| Prognosis | 1 | 2019 | 840 | 0.140 |
Why?
|
| Recovery of Function | 4 | 2012 | 290 | 0.140 |
Why?
|
| NF-kappa B | 4 | 2006 | 107 | 0.140 |
Why?
|
| Medial Collateral Ligament, Knee | 1 | 2016 | 7 | 0.140 |
Why?
|
| Osteoradionecrosis | 1 | 1995 | 2 | 0.140 |
Why?
|
| Synovitis | 1 | 2016 | 22 | 0.140 |
Why?
|
| Braces | 1 | 2016 | 26 | 0.140 |
Why?
|
| Interleukin-8 | 3 | 2006 | 32 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 402 | 0.140 |
Why?
|
| Mechanical Phenomena | 2 | 2017 | 22 | 0.140 |
Why?
|
| Arthralgia | 1 | 2017 | 121 | 0.140 |
Why?
|
| Leukocyte Count | 4 | 2020 | 92 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 68 | 0.130 |
Why?
|
| Osteoporosis | 1 | 2016 | 80 | 0.130 |
Why?
|
| Misonidazole | 1 | 2015 | 2 | 0.130 |
Why?
|
| Solubility | 3 | 2009 | 36 | 0.130 |
Why?
|
| Intermittent Pneumatic Compression Devices | 2 | 2011 | 7 | 0.130 |
Why?
|
| Fracture Fixation, Intramedullary | 2 | 2008 | 9 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 10 | 0.130 |
Why?
|
| Rats | 2 | 2016 | 854 | 0.130 |
Why?
|
| Postoperative Care | 2 | 2016 | 127 | 0.130 |
Why?
|
| Fetal Blood | 1 | 2014 | 16 | 0.130 |
Why?
|
| Phosphates | 2 | 2019 | 20 | 0.130 |
Why?
|
| Placenta | 1 | 2014 | 13 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 1995 | 13 | 0.130 |
Why?
|
| Environment | 1 | 2015 | 46 | 0.130 |
Why?
|
| Illinois | 2 | 2013 | 241 | 0.130 |
Why?
|
| Glioma | 1 | 2015 | 47 | 0.130 |
Why?
|
| Hypoxia | 1 | 2015 | 60 | 0.130 |
Why?
|
| Pain | 1 | 2018 | 391 | 0.130 |
Why?
|
| Mass Spectrometry | 2 | 2013 | 41 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 88 | 0.130 |
Why?
|
| Contraindications | 1 | 2014 | 41 | 0.120 |
Why?
|
| Nerve Net | 1 | 2014 | 54 | 0.120 |
Why?
|
| Trace Elements | 2 | 2007 | 4 | 0.120 |
Why?
|
| Seroma | 1 | 2014 | 5 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 100 | 0.120 |
Why?
|
| Interleukin-1 | 6 | 2003 | 78 | 0.120 |
Why?
|
| Chiroptera | 1 | 2013 | 1 | 0.120 |
Why?
|
| Adsorption | 1 | 2014 | 4 | 0.120 |
Why?
|
| Chemokines | 3 | 2014 | 29 | 0.120 |
Why?
|
| Blood Sedimentation | 4 | 2016 | 64 | 0.120 |
Why?
|
| Fibronectins | 1 | 2014 | 29 | 0.120 |
Why?
|
| Oncogene Protein v-akt | 1 | 2013 | 12 | 0.120 |
Why?
|
| Motion | 1 | 1993 | 24 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2014 | 24 | 0.120 |
Why?
|
| Sarcoma, Experimental | 2 | 1992 | 2 | 0.120 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 1113 | 0.120 |
Why?
|
| Complementary Therapies | 1 | 1994 | 15 | 0.120 |
Why?
|
| Electrophysiology | 1 | 2013 | 129 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2015 | 428 | 0.120 |
Why?
|
| World Health Organization | 1 | 2013 | 18 | 0.120 |
Why?
|
| Venous Thrombosis | 2 | 2011 | 42 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 16 | 0.120 |
Why?
|
| Photic Stimulation | 1 | 2013 | 44 | 0.120 |
Why?
|
| Models, Neurological | 1 | 2013 | 30 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2013 | 65 | 0.120 |
Why?
|
| Lysosomes | 1 | 2013 | 24 | 0.120 |
Why?
|
| Incidence | 1 | 2016 | 756 | 0.120 |
Why?
|
| Pregnancy | 1 | 2014 | 403 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 8 | 2008 | 263 | 0.120 |
Why?
|
| Heavy Metal Poisoning | 1 | 2013 | 2 | 0.120 |
Why?
|
| Particulate Matter | 1 | 2013 | 22 | 0.120 |
Why?
|
| Virginia | 1 | 2013 | 5 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 129 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2013 | 2 | 0.110 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2013 | 13 | 0.110 |
Why?
|
| Health Care Reform | 1 | 2013 | 20 | 0.110 |
Why?
|
| Interleukin-17 | 3 | 2021 | 27 | 0.110 |
Why?
|
| Body Fluids | 2 | 2010 | 19 | 0.110 |
Why?
|
| Brain | 1 | 2023 | 1689 | 0.110 |
Why?
|
| Equipment Design | 4 | 2012 | 185 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2013 | 16 | 0.110 |
Why?
|
| Electron Probe Microanalysis | 3 | 2004 | 5 | 0.110 |
Why?
|
| Memory, Short-Term | 1 | 2013 | 102 | 0.110 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1992 | 6 | 0.110 |
Why?
|
| Treatment Failure | 3 | 2016 | 159 | 0.110 |
Why?
|
| Cattle | 3 | 2021 | 217 | 0.110 |
Why?
|
| Anthropometry | 1 | 2012 | 37 | 0.110 |
Why?
|
| Interleukins | 1 | 2012 | 37 | 0.110 |
Why?
|
| Action Potentials | 1 | 2013 | 136 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 52 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 138 | 0.110 |
Why?
|
| Adaptation, Physiological | 2 | 2008 | 55 | 0.110 |
Why?
|
| beta Catenin | 1 | 2013 | 46 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 75 | 0.110 |
Why?
|
| Graphite | 1 | 2011 | 3 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 162 | 0.110 |
Why?
|
| Danazol | 1 | 2011 | 6 | 0.100 |
Why?
|
| Foreign-Body Migration | 5 | 2000 | 25 | 0.100 |
Why?
|
| Sarcoma | 1 | 1992 | 65 | 0.100 |
Why?
|
| Osteoprotegerin | 2 | 2008 | 7 | 0.100 |
Why?
|
| RANK Ligand | 2 | 2008 | 7 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2010 | 198 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 432 | 0.100 |
Why?
|
| Aluminum Oxide | 1 | 2011 | 7 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 130 | 0.100 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2011 | 5 | 0.100 |
Why?
|
| Mice, Knockout | 3 | 2019 | 303 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 7 | 0.100 |
Why?
|
| Cell Migration Inhibition | 2 | 2001 | 6 | 0.100 |
Why?
|
| Blood Coagulation | 1 | 2011 | 21 | 0.100 |
Why?
|
| Osteoarthritis | 5 | 2005 | 363 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2011 | 64 | 0.100 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2000 | 17 | 0.100 |
Why?
|
| Orientation | 1 | 2010 | 10 | 0.090 |
Why?
|
| Body Size | 1 | 2010 | 11 | 0.090 |
Why?
|
| Orthopedic Equipment | 1 | 2010 | 7 | 0.090 |
Why?
|
| Cisplatin | 2 | 1990 | 91 | 0.090 |
Why?
|
| Spectrum Analysis | 1 | 2010 | 9 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2012 | 226 | 0.090 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2010 | 23 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2013 | 264 | 0.090 |
Why?
|
| Device Approval | 1 | 2010 | 15 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 59 | 0.090 |
Why?
|
| Biological Factors | 1 | 2010 | 9 | 0.090 |
Why?
|
| Proteoglycans | 2 | 2004 | 337 | 0.090 |
Why?
|
| Pinealoma | 1 | 1989 | 2 | 0.090 |
Why?
|
| Goals | 1 | 2010 | 43 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2012 | 321 | 0.090 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 116 | 0.090 |
Why?
|
| Neutrophils | 1 | 2010 | 117 | 0.090 |
Why?
|
| Survival Analysis | 6 | 2017 | 298 | 0.090 |
Why?
|
| Necrosis | 2 | 2008 | 26 | 0.090 |
Why?
|
| Consumer Product Safety | 1 | 2009 | 3 | 0.090 |
Why?
|
| Pain, Postoperative | 3 | 2023 | 314 | 0.090 |
Why?
|
| Review Literature as Topic | 1 | 2009 | 10 | 0.090 |
Why?
|
| Health Policy | 1 | 2009 | 50 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 41 | 0.090 |
Why?
|
| Chromium Compounds | 1 | 2009 | 4 | 0.090 |
Why?
|
| Hydrogen | 1 | 2009 | 8 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 97 | 0.090 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2001 | 127 | 0.090 |
Why?
|
| Reimbursement, Incentive | 1 | 2008 | 6 | 0.090 |
Why?
|
| Physician Incentive Plans | 1 | 2008 | 2 | 0.090 |
Why?
|
| Phagocytes | 1 | 2009 | 23 | 0.090 |
Why?
|
| C-Reactive Protein | 3 | 2016 | 125 | 0.080 |
Why?
|
| Toxicity Tests | 1 | 2008 | 3 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2010 | 116 | 0.080 |
Why?
|
| Collagen | 2 | 2000 | 102 | 0.080 |
Why?
|
| Procollagen | 3 | 2004 | 10 | 0.080 |
Why?
|
| Tissue Distribution | 5 | 2019 | 42 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 324 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 101 | 0.080 |
Why?
|
| Lubrication | 1 | 2007 | 5 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2008 | 358 | 0.080 |
Why?
|
| Gamma Rays | 1 | 2007 | 16 | 0.080 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2007 | 4 | 0.080 |
Why?
|
| Databases, Protein | 1 | 2007 | 2 | 0.080 |
Why?
|
| Hip Fractures | 1 | 2008 | 32 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2007 | 14 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2016 | 298 | 0.080 |
Why?
|
| Registries | 3 | 2016 | 188 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2007 | 19 | 0.080 |
Why?
|
| Osteoclasts | 2 | 2006 | 19 | 0.080 |
Why?
|
| Adaptive Immunity | 2 | 2020 | 15 | 0.080 |
Why?
|
| Bone Transplantation | 2 | 2000 | 224 | 0.080 |
Why?
|
| Molecular Weight | 4 | 2014 | 45 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 56 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 132 | 0.070 |
Why?
|
| Technology Transfer | 1 | 2006 | 3 | 0.070 |
Why?
|
| Chicago | 4 | 2014 | 865 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2006 | 17 | 0.070 |
Why?
|
| Elbow Joint | 1 | 2008 | 131 | 0.070 |
Why?
|
| Chemokine CCL2 | 2 | 2006 | 20 | 0.070 |
Why?
|
| Publishing | 1 | 2006 | 38 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 57 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 788 | 0.070 |
Why?
|
| Research | 1 | 2006 | 54 | 0.070 |
Why?
|
| Tendon Injuries | 2 | 2005 | 196 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2021 | 109 | 0.070 |
Why?
|
| Osteotomy | 3 | 2003 | 163 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2018 | 638 | 0.070 |
Why?
|
| Debridement | 1 | 2006 | 100 | 0.070 |
Why?
|
| Cell Shape | 1 | 2005 | 8 | 0.070 |
Why?
|
| Oxides | 2 | 2019 | 12 | 0.070 |
Why?
|
| Histocytochemistry | 1 | 2004 | 26 | 0.070 |
Why?
|
| Blotting, Northern | 2 | 2002 | 28 | 0.060 |
Why?
|
| Osteocalcin | 2 | 2021 | 19 | 0.060 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2005 | 74 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2002 | 159 | 0.060 |
Why?
|
| Calcitriol | 1 | 2004 | 7 | 0.060 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 79 | 0.060 |
Why?
|
| Diphosphonates | 1 | 2004 | 17 | 0.060 |
Why?
|
| Methylmethacrylates | 2 | 1994 | 4 | 0.060 |
Why?
|
| Protein Binding | 2 | 2001 | 127 | 0.060 |
Why?
|
| Culture Media, Conditioned | 6 | 2006 | 37 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2004 | 61 | 0.060 |
Why?
|
| Carbon | 2 | 2013 | 10 | 0.060 |
Why?
|
| Injection Site Reaction | 1 | 2023 | 1 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2005 | 80 | 0.060 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2003 | 6 | 0.060 |
Why?
|
| Arthroplasty | 1 | 2004 | 136 | 0.060 |
Why?
|
| Comorbidity | 2 | 2018 | 498 | 0.060 |
Why?
|
| Arthritis | 2 | 2008 | 107 | 0.060 |
Why?
|
| DNA | 5 | 2005 | 125 | 0.060 |
Why?
|
| Kinetics | 1 | 2003 | 225 | 0.060 |
Why?
|
| Arthritis, Experimental | 1 | 2004 | 125 | 0.060 |
Why?
|
| Rabbits | 1 | 2003 | 280 | 0.060 |
Why?
|
| Transcription, Genetic | 3 | 2002 | 108 | 0.060 |
Why?
|
| Cell Cycle | 3 | 1999 | 41 | 0.060 |
Why?
|
| Femoral Fractures | 2 | 2001 | 41 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 4 | 2002 | 145 | 0.060 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2013 | 2 | 0.060 |
Why?
|
| Proteomics | 1 | 2023 | 91 | 0.050 |
Why?
|
| Culture Media | 1 | 2002 | 38 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 843 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2002 | 20 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2000 | 70 | 0.050 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2002 | 6 | 0.050 |
Why?
|
| Motor Activity | 1 | 2005 | 369 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2002 | 99 | 0.050 |
Why?
|
| Microdialysis | 1 | 2021 | 2 | 0.050 |
Why?
|
| Infant | 1 | 2023 | 531 | 0.050 |
Why?
|
| Acrocephalosyndactylia | 1 | 2001 | 1 | 0.050 |
Why?
|
| Vitamin E | 1 | 2021 | 27 | 0.050 |
Why?
|
| Aneurysm, Ruptured | 1 | 2001 | 16 | 0.050 |
Why?
|
| Transplantation, Homologous | 4 | 2005 | 277 | 0.050 |
Why?
|
| Skull | 1 | 2021 | 25 | 0.050 |
Why?
|
| Intracranial Aneurysm | 1 | 2001 | 30 | 0.050 |
Why?
|
| Bone Nails | 1 | 2001 | 17 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2001 | 11 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2021 | 57 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 38 | 0.050 |
Why?
|
| Immunoassay | 1 | 2021 | 41 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2001 | 40 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2021 | 65 | 0.050 |
Why?
|
| Fractures, Ununited | 1 | 2001 | 19 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 2013 | 97 | 0.050 |
Why?
|
| Gene Expression | 3 | 2010 | 226 | 0.050 |
Why?
|
| X-Ray Microtomography | 1 | 2021 | 72 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2013 | 125 | 0.050 |
Why?
|
| Arthroscopy | 2 | 2006 | 811 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2001 | 113 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 21 | 0.050 |
Why?
|
| Cadaver | 2 | 2018 | 359 | 0.050 |
Why?
|
| Specialty Boards | 1 | 2020 | 6 | 0.050 |
Why?
|
| Autopsy | 2 | 1999 | 335 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 23 | 0.050 |
Why?
|
| Finite Element Analysis | 1 | 2020 | 44 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 2020 | 8 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 65 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2000 | 112 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2021 | 132 | 0.050 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2020 | 15 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 45 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2020 | 47 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 140 | 0.040 |
Why?
|
| Xylenes | 1 | 2019 | 2 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 172 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 67 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2001 | 150 | 0.040 |
Why?
|
| Skin Tests | 1 | 2019 | 14 | 0.040 |
Why?
|
| Bone Screws | 2 | 2018 | 181 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2019 | 8 | 0.040 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 1999 | 2 | 0.040 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 1999 | 3 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1999 | 11 | 0.040 |
Why?
|
| Oncogenes | 1 | 1999 | 13 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2019 | 36 | 0.040 |
Why?
|
| School Admission Criteria | 1 | 2019 | 10 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1999 | 22 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 29 | 0.040 |
Why?
|
| Early Ambulation | 2 | 2011 | 20 | 0.040 |
Why?
|
| Magnetoencephalography | 1 | 2018 | 5 | 0.040 |
Why?
|
| Personnel Selection | 1 | 2019 | 23 | 0.040 |
Why?
|
| Equipment Reuse | 1 | 2018 | 3 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 12 | 0.040 |
Why?
|
| Swine | 1 | 2018 | 80 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 42 | 0.040 |
Why?
|
| Preoperative Care | 2 | 2011 | 135 | 0.040 |
Why?
|
| Mentoring | 1 | 2019 | 29 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2018 | 19 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 36 | 0.040 |
Why?
|
| Leadership | 1 | 2019 | 96 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2017 | 10 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 32 | 0.040 |
Why?
|
| Deep Brain Stimulation | 1 | 2018 | 74 | 0.040 |
Why?
|
| Self Administration | 1 | 2017 | 36 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 324 | 0.040 |
Why?
|
| Spectrophotometry, Atomic | 2 | 1999 | 4 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 724 | 0.040 |
Why?
|
| Biopsy | 2 | 2000 | 234 | 0.040 |
Why?
|
| Chromium Isotopes | 1 | 1996 | 1 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 1994 | 25 | 0.040 |
Why?
|
| Lipopeptides | 1 | 2016 | 11 | 0.040 |
Why?
|
| Vasculitis | 1 | 2016 | 32 | 0.040 |
Why?
|
| Risk | 1 | 2017 | 217 | 0.040 |
Why?
|
| Mitral Valve | 1 | 1996 | 13 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 1996 | 22 | 0.040 |
Why?
|
| Carcinogens | 1 | 2016 | 7 | 0.040 |
Why?
|
| Chelating Agents | 1 | 2016 | 11 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2007 | 82 | 0.040 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1995 | 7 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1995 | 16 | 0.030 |
Why?
|
| Pelvic Neoplasms | 1 | 1995 | 7 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 127 | 0.030 |
Why?
|
| Thyroid Diseases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2016 | 58 | 0.030 |
Why?
|
| Malnutrition | 1 | 2016 | 20 | 0.030 |
Why?
|
| Radionuclide Imaging | 3 | 1992 | 56 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 1995 | 113 | 0.030 |
Why?
|
| Brachytherapy | 1 | 1995 | 47 | 0.030 |
Why?
|
| Mice, Inbred DBA | 3 | 2004 | 50 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2016 | 41 | 0.030 |
Why?
|
| Dinoprostone | 4 | 1997 | 30 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2015 | 24 | 0.030 |
Why?
|
| Joint Instability | 2 | 2016 | 387 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2014 | 12 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2016 | 73 | 0.030 |
Why?
|
| New York City | 1 | 2014 | 18 | 0.030 |
Why?
|
| Calcium Radioisotopes | 1 | 1994 | 4 | 0.030 |
Why?
|
| Prostaglandins E | 1 | 1994 | 5 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1994 | 26 | 0.030 |
Why?
|
| Bisbenzimidazole | 1 | 1994 | 1 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 1994 | 12 | 0.030 |
Why?
|
| Probability | 2 | 2004 | 94 | 0.030 |
Why?
|
| Femur Neck | 1 | 2014 | 18 | 0.030 |
Why?
|
| Resource Allocation | 1 | 1994 | 6 | 0.030 |
Why?
|
| Interferometry | 1 | 2013 | 5 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2013 | 7 | 0.030 |
Why?
|
| Ethics Committees, Research | 1 | 1994 | 4 | 0.030 |
Why?
|
| Federal Government | 1 | 1994 | 6 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 1994 | 12 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2013 | 23 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2013 | 4 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 46 | 0.030 |
Why?
|
| Organoplatinum Compounds | 2 | 1992 | 7 | 0.030 |
Why?
|
| Information Dissemination | 1 | 1994 | 23 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 1994 | 42 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 1992 | 23 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 145 | 0.030 |
Why?
|
| Ibuprofen | 1 | 2013 | 12 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 162 | 0.030 |
Why?
|
| Cell Membrane | 3 | 2002 | 105 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 1993 | 14 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 161 | 0.030 |
Why?
|
| Cathepsin B | 1 | 2013 | 4 | 0.030 |
Why?
|
| Prejudice | 1 | 1994 | 38 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 1994 | 25 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 1994 | 49 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2013 | 13 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 11 | 0.030 |
Why?
|
| Base Sequence | 3 | 2002 | 134 | 0.030 |
Why?
|
| Melanoma | 1 | 1994 | 52 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 441 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 64 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2002 | 246 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 10 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2013 | 10 | 0.030 |
Why?
|
| Hip Injuries | 1 | 2013 | 11 | 0.030 |
Why?
|
| Medical Device Recalls | 1 | 2012 | 3 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 330 | 0.030 |
Why?
|
| Organotechnetium Compounds | 1 | 1992 | 8 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2013 | 174 | 0.030 |
Why?
|
| Hardness | 1 | 2012 | 6 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 175 | 0.030 |
Why?
|
| Microscopy | 1 | 2012 | 12 | 0.030 |
Why?
|
| Electrons | 1 | 2012 | 19 | 0.030 |
Why?
|
| Temperature | 1 | 2012 | 76 | 0.030 |
Why?
|
| Spectroscopy, Electron Energy-Loss | 1 | 2011 | 3 | 0.030 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2011 | 4 | 0.030 |
Why?
|
| Serum | 1 | 2011 | 9 | 0.030 |
Why?
|
| New Zealand | 1 | 2011 | 13 | 0.030 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 7 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2011 | 16 | 0.030 |
Why?
|
| Pressure | 1 | 2012 | 59 | 0.030 |
Why?
|
| Australia | 1 | 2011 | 44 | 0.030 |
Why?
|
| International Cooperation | 1 | 2011 | 32 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 17 | 0.030 |
Why?
|
| United Kingdom | 1 | 2011 | 50 | 0.030 |
Why?
|
| Anesthesia, Epidural | 1 | 2011 | 25 | 0.030 |
Why?
|
| Specimen Handling | 1 | 1991 | 48 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 64 | 0.030 |
Why?
|
| Hemophilia A | 1 | 2011 | 41 | 0.030 |
Why?
|
| Genes, myc | 1 | 2011 | 6 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 407 | 0.020 |
Why?
|
| Benzoquinones | 1 | 2011 | 3 | 0.020 |
Why?
|
| Tubulin | 1 | 2011 | 16 | 0.020 |
Why?
|
| Acetylation | 1 | 2011 | 13 | 0.020 |
Why?
|
| Lactams, Macrocyclic | 1 | 2011 | 10 | 0.020 |
Why?
|
| Reducing Agents | 1 | 2010 | 3 | 0.020 |
Why?
|
| Free Radicals | 1 | 2010 | 9 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Metallurgy | 1 | 1990 | 2 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 77 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 21 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 125 | 0.020 |
Why?
|
| Ultrafiltration | 1 | 2010 | 6 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2010 | 7 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2010 | 12 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2010 | 12 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 2010 | 5 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 76 | 0.020 |
Why?
|
| Marketing | 1 | 2010 | 3 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 56 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 36 | 0.020 |
Why?
|
| Imino Acids | 1 | 1990 | 2 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1990 | 2 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2010 | 69 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2011 | 100 | 0.020 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2011 | 118 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 226 | 0.020 |
Why?
|
| NADP | 1 | 2009 | 9 | 0.020 |
Why?
|
| Phenotype | 1 | 2011 | 355 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 153 | 0.020 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2009 | 1 | 0.020 |
Why?
|
| Kallikreins | 1 | 2009 | 2 | 0.020 |
Why?
|
| Bradykinin Receptor Antagonists | 1 | 2009 | 2 | 0.020 |
Why?
|
| Bradykinin | 1 | 2009 | 4 | 0.020 |
Why?
|
| Androgens | 1 | 2009 | 8 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2002 | 170 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 340 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2009 | 3 | 0.020 |
Why?
|
| Patellofemoral Joint | 1 | 2010 | 52 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2008 | 10 | 0.020 |
Why?
|
| Mortality | 1 | 2009 | 86 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2008 | 35 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 95 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 340 | 0.020 |
Why?
|
| Connective Tissue | 1 | 2007 | 25 | 0.020 |
Why?
|
| Population Dynamics | 1 | 2007 | 11 | 0.020 |
Why?
|
| Professional Practice | 1 | 2007 | 10 | 0.020 |
Why?
|
| Economics | 1 | 2007 | 18 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2007 | 47 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2007 | 53 | 0.020 |
Why?
|
| Technetium | 1 | 1987 | 7 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2006 | 7 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 107 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2007 | 62 | 0.020 |
Why?
|
| Reference Values | 2 | 1998 | 227 | 0.020 |
Why?
|
| Calcium | 3 | 1997 | 491 | 0.020 |
Why?
|
| Cytochalasin D | 1 | 2006 | 6 | 0.020 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2006 | 7 | 0.020 |
Why?
|
| Supine Position | 1 | 2006 | 15 | 0.020 |
Why?
|
| Ethics, Clinical | 1 | 2005 | 1 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2005 | 12 | 0.020 |
Why?
|
| Organ Culture Techniques | 2 | 1997 | 31 | 0.020 |
Why?
|
| Physicians | 1 | 2007 | 115 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 1184 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 38 | 0.020 |
Why?
|
| Osteonectin | 1 | 2004 | 6 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 16 | 0.020 |
Why?
|
| Rupture | 1 | 2004 | 115 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2004 | 13 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2004 | 80 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2004 | 35 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2004 | 65 | 0.020 |
Why?
|
| Exercise Test | 1 | 2005 | 122 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2003 | 28 | 0.020 |
Why?
|
| Antibodies | 1 | 2004 | 65 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 80 | 0.010 |
Why?
|
| Exercise | 1 | 2007 | 468 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 364 | 0.010 |
Why?
|
| Amino Acids | 1 | 2002 | 20 | 0.010 |
Why?
|
| RNA, Neoplasm | 2 | 1994 | 17 | 0.010 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 12 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 9 | 0.010 |
Why?
|
| Glycosylation | 1 | 2002 | 24 | 0.010 |
Why?
|
| Tyrosine | 1 | 2002 | 23 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 145 | 0.010 |
Why?
|
| Osteogenesis | 1 | 2002 | 96 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 145 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 2001 | 29 | 0.010 |
Why?
|
| Fracture Healing | 1 | 2001 | 40 | 0.010 |
Why?
|
| Methods | 1 | 2000 | 18 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 56 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 109 | 0.010 |
Why?
|
| Prevalence | 1 | 2001 | 487 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2001 | 642 | 0.010 |
Why?
|
| Biodegradation, Environmental | 1 | 1999 | 4 | 0.010 |
Why?
|
| Structure-Activity Relationship | 2 | 1990 | 44 | 0.010 |
Why?
|
| Rotation | 1 | 1998 | 142 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1999 | 156 | 0.010 |
Why?
|
| Fetus | 1 | 1998 | 56 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1998 | 106 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1998 | 99 | 0.010 |
Why?
|
| Aggrecans | 1 | 1998 | 146 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1997 | 96 | 0.010 |
Why?
|
| Gentamicins | 1 | 1976 | 16 | 0.010 |
Why?
|
| Microscopy, Polarization | 1 | 1996 | 3 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1997 | 123 | 0.010 |
Why?
|
| Bone Wires | 1 | 1996 | 13 | 0.010 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1996 | 4 | 0.010 |
Why?
|
| Aortic Valve | 1 | 1996 | 22 | 0.010 |
Why?
|
| Hip Dislocation | 1 | 1997 | 65 | 0.010 |
Why?
|
| Pulmonary Edema | 1 | 1996 | 19 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1995 | 14 | 0.010 |
Why?
|
| Hydroxyproline | 1 | 1995 | 7 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 1995 | 24 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1995 | 26 | 0.010 |
Why?
|
| Fibrosis | 1 | 1995 | 39 | 0.010 |
Why?
|
| Chromomycin A3 | 1 | 1994 | 1 | 0.010 |
Why?
|
| Monophenol Monooxygenase | 1 | 1994 | 1 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1994 | 50 | 0.010 |
Why?
|
| Microspheres | 1 | 1994 | 32 | 0.010 |
Why?
|
| Indomethacin | 1 | 1993 | 9 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1994 | 146 | 0.010 |
Why?
|
| Osteonecrosis | 1 | 1993 | 19 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 251 | 0.010 |
Why?
|
| Hip | 1 | 1993 | 40 | 0.010 |
Why?
|
| Ossification, Heterotopic | 1 | 1993 | 42 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1994 | 254 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1990 | 14 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1990 | 20 | 0.010 |
Why?
|
| Carboplatin | 1 | 1990 | 49 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1990 | 55 | 0.010 |
Why?
|
| Virus Replication | 1 | 1990 | 92 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1987 | 14 | 0.000 |
Why?
|
| Papio | 1 | 1984 | 9 | 0.000 |
Why?
|
| Tensile Strength | 1 | 1976 | 29 | 0.000 |
Why?
|